These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 11960487)

  • 1. Structure-based design of novel potent nonpeptide thrombin inhibitors.
    Hauel NH; Nar H; Priepke H; Ries U; Stassen JM; Wienen W
    J Med Chem; 2002 Apr; 45(9):1757-66. PubMed ID: 11960487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.
    Ieko M
    Curr Opin Investig Drugs; 2007 Sep; 8(9):758-68. PubMed ID: 17729188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
    Eisert WG; Hauel N; Stangier J; Wienen W; Clemens A; van Ryn J
    Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1885-9. PubMed ID: 20671233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
    Das J; Kimball SD; Hall SE; Han WC; Iwanowicz E; Lin J; Moquin RV; Reid JA; Sack JS; Malley MF; Chang CY; Chong S; Wang-Iverson DB; Roberts DG; Seiler SM; Schumacher WA; Ogletree ML
    Bioorg Med Chem Lett; 2002 Jan; 12(1):45-9. PubMed ID: 11738570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
    Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
    J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.
    Phillips GB; Buckman BO; Davey DD; Eagen KA; Guilford WJ; Hinchman J; Ho E; Koovakkat S; Liang A; Light DR; Mohan R; Ng HP; Post JM; Shaw KJ; Smith D; Subramanyam B; Sullivan ME; Trinh L; Vergona R; Walters J; White K; Whitlow M; Wu S; Xu W; Morrissey MM
    J Med Chem; 1998 Sep; 41(19):3557-62. PubMed ID: 9733480
    [No Abstract]   [Full Text] [Related]  

  • 7. Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
    Das J; Kimball SD; Reid JA; Wang TC; Lau WF; Roberts DG; Seiler SM; Schumacher WA; Ogletree ML
    Bioorg Med Chem Lett; 2002 Jan; 12(1):41-4. PubMed ID: 11738569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Wang S; Fevig JM; Quan ML; Amparo E; Cacciola J; Rossi KA; Alexander RS; Smallwood AM; Luettgen JM; Liang L; Aungst BJ; Wright MR; Knabb RM; Wong PC; Wexler RR; Lam PY
    J Med Chem; 2001 Feb; 44(4):566-78. PubMed ID: 11170646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological activity of novel factor Xa inhibitors: 4-aryloxy substituents of 2,6-diphenoxypyridines.
    Ng HP; Buckman BO; Eagen KA; Guilford WJ; Kochanny MJ; Mohan R; Shaw KJ; Wu SC; Lentz D; Liang A; Trinh L; Ho E; Smith D; Subramanyam B; Vergona R; Walters J; White KA; Sullivan ME; Morrissey MM; Phillips GB
    Bioorg Med Chem; 2002 Mar; 10(3):657-66. PubMed ID: 11814853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
    Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
    Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amidinohydrazones as guanidine bioisosteres: application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors.
    Soll RM; Lu T; Tomczuk B; Illig CR; Fedde C; Eisennagel S; Bone R; Murphy L; Spurlino J; Salemme FR
    Bioorg Med Chem Lett; 2000 Jan; 10(1):1-4. PubMed ID: 10636229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of ligand conformations in continuum solvent consistent with protein active site topology: application to thrombin.
    Greenidge PA; Mérette SA; Beck R; Dodson G; Goodwin CA; Scully MF; Spencer J; Weiser J; Deadman JJ
    J Med Chem; 2003 Apr; 46(8):1293-305. PubMed ID: 12672230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
    Parlow JJ; Case BL; Dice TA; Fenton RL; Hayes MJ; Jones DE; Neumann WL; Wood RS; Lachance RM; Girard TJ; Nicholson NS; Clare M; Stegeman RA; Stevens AM; Stallings WC; Kurumbail RG; South MS
    J Med Chem; 2003 Sep; 46(19):4050-62. PubMed ID: 12954058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
    Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
    J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent bicyclic lactam inhibitors of thrombin: Part I: P3 modifications.
    St-Denis Y; Augelli-Szafran CE; Bachand B; Berryman KA; DiMaio J; Doherty AM; Edmunds JJ; Leblond L; Lévesque S; Narasimhan LS; Penvose-Yi JR; Rubin JR; Tarazi M; Winocour PD; Siddiqui MA
    Bioorg Med Chem Lett; 1998 Nov; 8(22):3193-8. PubMed ID: 9873701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template.
    Jhoti H; Cleasby A; Reid S; Thomas PJ; Weir M; Wonacott A
    Biochemistry; 1999 Jun; 38(25):7969-77. PubMed ID: 10387040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate.
    Yang XZ; Diao XJ; Yang WH; Li F; He GW; Gong GQ; Xu YG
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2089-92. PubMed ID: 23466230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
    Tucker TJ; Brady SF; Lumma WC; Lewis SD; Gardell SJ; Naylor-Olsen AM; Yan Y; Sisko JT; Stauffer KJ; Lucas BJ; Lynch JJ; Cook JJ; Stranieri MT; Holahan MA; Lyle EA; Baskin EP; Chen IW; Dancheck KB; Krueger JA; Cooper CM; Vacca JP
    J Med Chem; 1998 Aug; 41(17):3210-9. PubMed ID: 9703466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.